SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MorphoSys AG (MOR)
An SI Board Since January 2000
Posts SubjectMarks Bans
421 15 0
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
396 MorphoSys Completes Sale of AbD Serotec to Bio-Rad January 10, 2013 / 3:30 pGermanecki-2/8/2013
395 Bio-Rad to Acquire MorphoSys's Research and Diagnostic Antibody Business AGermanecki-2/8/2013
394 MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202 DecGermanecki-2/8/2013
393 MorphoSys and Lanthio Pharma Sign Technology Alliance on New Class of TherapeuGermanecki-11/29/2012
392 MorphoSys Reports Successful Phase 1 Study of MOR103 Using a Subcutaneous AdmiGermanecki-11/29/2012
391MorphoSys Announces Expansion of Antibody Alliance . November 07, 2012 / 7:0Germanecki-11/11/2012
390MorphoSys AG Reports Nine Months 2012 Results . November 07, 2012 / 6:59 am, CGermanecki-11/11/2012
389MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208 at 201Germanecki-11/11/2012
388MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574 . November 05,Germanecki-11/11/2012
387ACR-Late Breaking Abstract Accepted: MorphoSys to Present Clinical Data on MOR10Germanecki-11/6/2012
386Chart [graphic]Germanecki-9/21/2012
385Latest Webcast 09/21/2012 - Conference Call and Webcast: Clinical Trial ResultsGermanecki-9/21/2012
384MorphoSys's MOR103 Antibody Demonstrates Excellent Safety and Efficacy in RhGermanecki-9/21/2012
383MorphoSys and the University of Melbourne Publish Preclinical Data on the Role oGermanecki-9/10/2012
382Roche sees Morphosys Gantenerumab against Alzheimer in the pool position! RocGermanecki-9/7/2012
381GM-CSF Suppression May Alleviate Pain From Arthritis Posted on August 24, 2012Germanecki-8/30/2012
380MorphoSys AG : Publication pursuant to §26 sect.1 WpHG (the German SecuritiGermanecki-8/24/2012
379 MorphoSys AG Reports Results for the First Six Months of 2012 August 02, 201Germanecki-8/10/2012
378MOR103 Phase 2 Efficacy Study in Patients With Active Rheumatoid Arthritis is noGermanecki-7/18/2012
377MorphoSys AG : Publication pursuant to §26 sect.1 WpHG (the German SecuritiGermanecki-7/7/2012
376MorphoSys Partner OncoMed Publishes Data on HuCAL Antibody OMP-18R5 July 05, 201Germanecki-7/7/2012
375MorphoSys AG : Publication pursuant to §26 sect.1 WpHG (the German SecuritiGermanecki-6/25/2012
374Yeah, I'd like to see them do with more of their pipeline what they are doinmcbio-6/22/2012
373@mcbio, mid single digit for royalities is very good! Morphosys is only deliveGermanecki-6/22/2012
372Is there any particular reason why MorphoSys is never apparently able to negotiamcbio-6/20/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News